Biogen Inc
Biogen Inc is a biotechnology company that develops therapies for the treatment of neurological, autoimmune, and rare diseases.
Price history of Biogen Inc
Price history of Biogen Inc
Performance & Momentum
Biogen advances LEQEMBI trials and China approval
Biogen (NASDAQ: BIIB) is making positive progress with accelerated timelines announced for the Phase 3 EMPEROR study targeting Dravet syndrome, developed in partnership with Stoke Therapeutics. Additionally, the submission for a home-injectable version of its Alzheimer’s treatment LEQEMBI has been accepted by Chinese regulators, paving the way for broader accessibility in a high-demand market. These developments strengthen Biogen’s position in innovative biopharma and are expected to support its stock momentum.
Similar stocks to Biogen Inc
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
